Member Info for Laura2022

No shares at 15p

Not surprised with only 10% free float

28 minutes ago

The UK government will unveil a new Defence Industrial Strategy (DIS) on Monday, backed by £250m in funding, to support regional economic growth and boost innovation in the defence sector.

Defence Secretary John Healey will launch the strategy during a visit to Bristol-based defence tech firm Rowden on 8 September, to open its new facility.

Just thankful I had the opportunity to buy more at 10p, 11p and 11.8p over last 2 weeks

If

You want a PRODUCING PROFITABLE gold miner valued 1/4 of some exploration stocks

Look at GDP (Goldplat)

Of course do.research etc

Only got a small amount so far but the more I read this weekend it seems insanely undervalued

£15mln, profitable , cash generative amd once cash is taken off the whole business valued at pittance

There are 2 other events , Manchester and Bristol also

More.will be known in November,

WH Smith boss Chris Cowling and former finance director Robert Moorhead were paid £2.7 million and £1.9 million respectively last year – mostly in performance-related bonuses.

A WHSmith insider said 'it shouldn't be a surprise' that supplier income had increased as the company expanded. They pointed out that group sales have almost doubled since 2019, when supplier income was £10 million.

The findings of Deloitte's investigation may be published when WHSmith releases its results in November. Profits for the year to August are now expected to be £110 million, the company said, down from previous estimates of £160 million.

WHSmith, its auditors PwC and Deloitte declined to comment.

Aim 50k tonnes per year and a total of 40mln tonnes

Quick listen

Flurospar grades worldwide

Low - 5-10%

Medium/economic 25%

High - REE grades are up to 90% !

Open pit and easy , building on May 2025 work ,

Sept - drilling to get fresh resource estimate and samples then quickly into scoping study for Q12026

Q3 2026 final investment decision/DFS

Q3 2027 production

Aim is for Flurospar to fund other projects and not come back to market

Also mentioned US help f0r rare earths

Thabks kindly smkr

Morning cavalier

Yes, their toxic rants have now been seen for wjat they are and thankfully more peope like your good self are exposing it

Muck

Those 3 filtered ones have waged a 3mth campaign here, for not entirely clear reasons

Amassing 100s of posts on here, almost 98% of their posts

They've changed their stories so many times, eg Bassman72 saying he held, sold, but now holds

Waste of time

For those looking at other cash generating profitable gold plays i stunned

Bled across GDP ( goldplat), not in same league as PAF but very cheap nonetheless

since publication of the sdr, the company has seen a marked increase in customer engagement. several previously dormant discussions with major contractors have resumed, and the company is now progressing a potentially significant partnership with one of the uk's leading defence contractors. "

this may well be bab**** international as both companies mentioned it on linkedin late august

3 rcfx directors have purchased shares

3 investors events planned sept 2025

Muck

Morning, and they clearly stated that SINCE the defence review, major customers had returned for discussions

Harvard University

The average new drug requires over 15 years and $2 billion in funding to traverse the journey from discovery to full approval. The first portion of the journey, among the riskiest and most scientifically complex portions, involves extensive testing of the drug in in silico, in vitro, and in vivo settings. Current standards all but ensure that new medicines are tested extensively in vivo animal models for safety before being permitted in patients.

But a tidal shift is underway. In vivo models are being complemented by, and in some cases supplanted by, more sophisticated in vitro and computational preclinical models that can substantially reduce the cost and timeline of early-stage drug development.

23h

A big shift is underway in drug development.

As this recent article from the Wyss Institute at Harvard University and colleagues highlights, traditional reliance on animal models is giving way to more human-relevant approaches – from advanced in vitro systems to computational / in silico tools. Regulators are starting to recognise their value too, with frameworks emerging to encourage wider adoption.

At Physiomics plc, we see Model-Informed Drug Development (MIDD) as central to this transformation. By applying QSP, PK/PD and population modelling, we help drug developers use their data to predict outcomes earlier and optimise study design with confidence. By reducing over-reliance on animal studies with simulations that can supplement existing data, and also simulate human biology, we help reduce the time and cost associated with trial-and-error in in vivo systems.

It’s encouraging to see the field moving towards approaches that not only promise more reliable drug development, but also align closely with the work we’re already doing with our partners.

📄 Read the full article 👇

https://lnkd.in/e9UAu2pp

Goldplat is a profitable, African gold recovery services company with two market leading operations in South Africa and Ghana. Goldplat’s strategy is focussed on utilising its robust cash flow generated from flagship gold recovery operations in Africa to self-fund sustainable growth and expansion of niche gold recovery business model.

Gold price on Friday was $3594.55 while September Comex gold GCU25 closed a few hours later at $3600.80.

J5/aklee

Other 98% must be JD then , thats all he ever posted on